Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies
Mona H Ismail1, Massimo Pinzani21Department of Internal Medicine, Division of Gastroenterology, King Fahad University Hospital, Al-Khobar, Saudi Arabia; 2Dipartimento di Medicina Interna Center for Research, High Education and Transfer, Università degli Studi di Firenze, Florence, Ita...
Guardado en:
Autores principales: | Ismail MH, Pinzani M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/14387ca6c1a342c2a360002dbe44a264 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Serum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis
por: Suad Abdeen, et al.
Publicado: (2011) -
Antiviral therapy for chronic hepatitis B in the indeterminate phase is urgent
por: JIANG Jun
Publicado: (2021) -
Interferon-free combination therapies for the treatment of hepatitis C: current insights
por: Holmes JA, et al.
Publicado: (2015) -
Scavenger receptor class B member 1 protein: hepatic regulation and its effects on lipids, reverse cholesterol transport, and atherosclerosis
por: Kent AP, et al.
Publicado: (2011) -
How far are we from the “Treat all” era of antiviral therapy for chronic hepatitis B
por: DING Yang
Publicado: (2021)